These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 22935938)

  • 1. Direct thrombin inhibitors for management of heparin-induced thrombocytopenia in patients receiving renal replacement therapy: comparison of clinical outcomes.
    Abel EE; Kane-Gill SL; Seybert AL; Kellum JA
    Am J Health Syst Pharm; 2012 Sep; 69(18):1559-67. PubMed ID: 22935938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of bivalirudin to lepirudin and argatroban in patients with heparin-induced thrombocytopenia.
    Bain J; Meyer A
    Am J Health Syst Pharm; 2015 Sep; 72(17 Suppl 2):S104-9. PubMed ID: 26272889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia.
    Dang CH; Durkalski VL; Nappi JM
    Pharmacotherapy; 2006 Apr; 26(4):461-8. PubMed ID: 16553503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia.
    Skrupky LP; Smith JR; Deal EN; Arnold H; Hollands JM; Martinez EJ; Micek ST
    Pharmacotherapy; 2010 Dec; 30(12):1229-38. PubMed ID: 21114390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban.
    Warkentin TE
    Thromb Res; 2003 May; 110(2-3):73-82. PubMed ID: 12893020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.
    Kiser TH; Jung R; MacLaren R; Fish DN
    Pharmacotherapy; 2005 Dec; 25(12):1736-45. PubMed ID: 16305293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of direct thrombin inhibitors in the treatment of Heparin-Induced Thrombocytopenia: a single institution experience.
    Curzio KM; Cheng-Lai A; Kheyfets V; Sinnet M; Billett HH
    J Thromb Thrombolysis; 2009 Aug; 28(2):117-23. PubMed ID: 18827975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial.
    Treschan TA; Schaefer MS; Geib J; Bahlmann A; Brezina T; Werner P; Golla E; Greinacher A; Pannen B; Kindgen-Milles D; Kienbaum P; Beiderlinden M
    Crit Care; 2014 Oct; 18(5):588. PubMed ID: 25344113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of bivalirudin dose with creatinine clearance during treatment of heparin-induced thrombocytopenia.
    Runyan CL; Cabral KP; Riker RR; Redding D; May T; Seder DB; Savic M; Hedlund J; Abramson S; Fraser GL
    Pharmacotherapy; 2011 Sep; 31(9):850-6. PubMed ID: 21923585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of argatroban and bivalirudine in patients with suspected heparin-induced thrombocytopenia.
    Vo QA; Lin JK; Tong LM
    Ann Pharmacother; 2015 Feb; 49(2):178-84. PubMed ID: 25515865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Argatroban therapy for heparin-induced thrombocytopenia in acutely ill patients.
    Gray A; Wallis DE; Hursting MJ; Katz E; Lewis BE
    Clin Appl Thromb Hemost; 2007 Oct; 13(4):353-61. PubMed ID: 17911186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment options for heparin-induced thrombocytopenia.
    Greinacher A
    Am J Health Syst Pharm; 2003 Oct; 60 Suppl 5():S12-8. PubMed ID: 14593978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.
    Lewis BE; Wallis DE; Leya F; Hursting MJ; Kelton JG;
    Arch Intern Med; 2003 Aug 11-25; 163(15):1849-56. PubMed ID: 12912723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia.
    Tsu LV; Dager WE
    Ann Pharmacother; 2011 Oct; 45(10):1185-92. PubMed ID: 21881032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a standardized protocol using lepirudin or argatroban for heparin-induced thrombocytopenia.
    Kennedy K; Steinke D; King S; Poe K; Reeves J; Short M
    Cardiovasc Hematol Agents Med Chem; 2011 Oct; 9(4):262-8. PubMed ID: 21902659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin-induced thrombocytopenia: treatment options and special considerations.
    Dager WE; Dougherty JA; Nguyen PH; Militello MA; Smythe MA
    Pharmacotherapy; 2007 Apr; 27(4):564-87. PubMed ID: 17381384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
    Lewis BE; Hursting MJ
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):57-68. PubMed ID: 17187457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction.
    Kiser TH; Fish DN
    Pharmacotherapy; 2006 Apr; 26(4):452-60. PubMed ID: 16553502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy.
    Reddy BV; Grossman EJ; Trevino SA; Hursting MJ; Murray PT
    Ann Pharmacother; 2005 Oct; 39(10):1601-5. PubMed ID: 16131539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro.
    Nielsen VG; Steenwyk BL; Gurley WQ; Pereira SJ; Lell WA; Kirklin JK
    J Heart Lung Transplant; 2006 Jun; 25(6):653-63. PubMed ID: 16730571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.